Novartis Pharma AG — Sponsor Intelligence | 224 EU Trials

Filter these 224 trials by condition, phase, country and more.

Open in Search →

224 Registered trials

70 Recruiting

133 Completed trials

26 Countries active

253 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 87 Phase II/III: 2 Phase II: 56 Phase I/II: 19 Phase III/IV: 2 Phase IV: 12 Phase I: 17 Phase I (Other): 18 Phase I (FiH): 11

Oversight events:

2 serious breaches 129 temporary halts 1 urgent safety measure 23 unexpected events 10 corrective measures across 53 trials

View oversight register →

100%

133 of 133 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 16 Systemic lupus erythematosus 7 Colorectal cancer 6 Sjogren's syndrome 5 Lupus nephritis 5 Chronic spontaneous urticaria 5 Relapsing multiple sclerosis 4 IgA nephropathy 4 Multiple sclerosis relapse 4 Hormone receptor positive HER2 negative breast cancer 4 Triple negative breast cancer 4 Giant cell arteritis 3

Top IMPs

IANALUMAB 16 REMIBRUTINIB 14 IPTACOPAN 13 LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN 9 RAPCABTAGENE AUTOLEUCEL 9 GOZETOTIDE 7 PELACARSEN 6 RIBOCICLIB 6 ASCIMINIB HYDROCHLORIDE 5 IPTACOPAN HYDROCHLORIDE 5 1-{6-[(4M)-4-(5-CHLORO-6-METHYL-1H -INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H -INDAZOL-5-YL)-1H -PYRAZOL-1-YL]-2-AZASPIRO[3.3]HEPTAN-2-YL}PROP-2-EN-1-ONE 4 ALPELISIB 4

All trials — page 7

224 total

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of … Ended

2024-513227-16-00 Phase III 6 countries ATRASENTAN HYDROCHLORIDE
Study to evaluate the efficacy and safety of MAS825 in patients with autoinflammatory diseases. Ended

2023-504419-34-00 Phase II 4 countries HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN IL-1 BETA AND HUMAN IL-18
Study of efficacy and safety of LXH254 combinations in patients with previously treated unresectable or metastatic melanoma Ended

2024-511934-11-00 Phase II 4 countries NAPORAFENIB; RIBOCICLIB; RINETERKIB; TRAMETINIB DIMETHYL SULFOXIDE
A research study to find out if the study treatment alpelisib (BYL719) is safe and can help others who have confirmed diagnosis of PIK3CA-re… Ended

2023-508530-34-00 Phase II 6 countries ALPELISIB
An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended

2023-507970-42-00 Phase III 10 countries GOZETOTIDE; LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Ended

2023-507062-34-00 Phase I (FiH) 5 countries RAPCABTAGENE AUTOLEUCEL
N/A Ended

2024-513086-39-00 Phase III 3 countries ONASEMNOGENE ABEPARVOVEC
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Phase III 20 countries PELACARSEN
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme… Ended

2023-508841-42-00 Phase I (Other) 8 countries 3-[6-(1-BENZYLPIPERIDIN-4-YL)-3-OXO-1H-ISOINDOL-2-YL]PIPERIDINE-2,6-DIONE; CAPMA…
This study will facilitate data collection of the long-term outcomes of pediatric subjects who have been treated in clinical trials with dab… Ended

2023-509276-42-00 Phase IV 10 countries DABRAFENIB MESYLATE; TRAMETINIB; TRAMETINIB DIMETHYL SULFOXIDE
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 Phase III 10 countries
Study of efficacy and safety of tisagenlecleucel in HR B-ALL EOC MRD positive patients Ended

2023-508081-15-00 Phase II 8 countries
A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr… Ended

2023-509834-20-00 Phase II 6 countries MIDOSTAURIN
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Phase III 21 countries B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/AUS…
Study to allow patients with cMET-dependent malignancies to continue capmatinib treatment Ended

2024-510948-31-00 Phase II 3 countries CAPMATINIB; NAZARTINIB
An open-label, multi-center rollover protocol for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are c… Ended

2024-511125-61-00 Phase I/II 2 countries NAZARTINIB; RIBOCICLIB
A study for patients who have completed a prior global Novartis sponsored ceritinib (LDK378) study and are judged by the investigator to ben… Ended

2024-511040-58-00 Phase IV 6 countries
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations Ended

2023-507421-41-00 Phase I 1 country
A clinical study to evaluate the efficacy of ceritinib in combination with nivolumab in patients with ALK positive lung cancer Ended

2024-510824-38-00 Phase I (Other) 2 countries
A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer Ended

2023-509511-84-00 Phase I/II 2 countries RIBOCICLIB
A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety and efficacy of fingolimod admi… Ended

2023-507556-68-00 Phase III 5 countries FINGOLIMOD
Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis Halted

2025-521503-43-00 Phase II 5 countries GIA632
Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta… Halted

2024-511708-18-00 Phase II 10 countries 1-{6-[(4M)-4-(5-CHLORO-6-METHYL-1H -INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H -INDAZ…
A Phase I/II study of DYP688 treatment alone in patients with eye cancer and other types of cancers of the skin and mucosal membranes in the… Halted

2023-509451-14-00 Phase I (FiH) 4 countries DYP688

Showing 145–168 of 224 trials

← All sponsors A–Z